CR20170080A - Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace - Google Patents

Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace

Info

Publication number
CR20170080A
CR20170080A CR20170080A CR20170080A CR20170080A CR 20170080 A CR20170080 A CR 20170080A CR 20170080 A CR20170080 A CR 20170080A CR 20170080 A CR20170080 A CR 20170080A CR 20170080 A CR20170080 A CR 20170080A
Authority
CR
Costa Rica
Prior art keywords
alzheimer
combination therapy
bace inhibitor
abeta antibodies
n3pglu abeta
Prior art date
Application number
CR20170080A
Other languages
English (en)
Inventor
Patrick Cornelious May
Dustin James Mergott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20170080A publication Critical patent/CR20170080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Massaging Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad neurodegenerativa o cognitiva, que comprende administrar a un paciente que necesite dicho tratamiento una cantidad eficaz de un compuesto de la fórmula: o una sal farmacéuticamente aceptable de este; en combinación con una cantidad eficaz de un anticuerpo monoclonal Abeta anti-N3pGlu.
CR20170080A 2014-09-16 2015-09-08 Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace CR20170080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050967P 2014-09-16 2014-09-16
PCT/US2015/048807 WO2016043997A1 (en) 2014-09-16 2015-09-08 Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor

Publications (1)

Publication Number Publication Date
CR20170080A true CR20170080A (es) 2017-03-30

Family

ID=54207720

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170080A CR20170080A (es) 2014-09-16 2015-09-08 Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace

Country Status (27)

Country Link
US (1) US9999624B2 (es)
EP (1) EP3193882A1 (es)
JP (1) JP6339741B2 (es)
KR (1) KR101871128B1 (es)
CN (1) CN106687136A (es)
AP (1) AP2017009794A0 (es)
AR (1) AR101740A1 (es)
AU (1) AU2015318257B2 (es)
BR (1) BR112017003571A2 (es)
CA (1) CA2956835A1 (es)
CL (1) CL2017000558A1 (es)
CO (1) CO2017001875A2 (es)
CR (1) CR20170080A (es)
DO (1) DOP2017000071A (es)
EA (1) EA031764B1 (es)
EC (1) ECSP17015977A (es)
IL (1) IL250387A0 (es)
MX (1) MX2017003414A (es)
NZ (1) NZ728636A (es)
PE (1) PE20170464A1 (es)
PH (1) PH12017500493A1 (es)
SG (1) SG11201701330PA (es)
SV (1) SV2017005389A (es)
TN (1) TN2017000072A1 (es)
TW (1) TWI599358B (es)
WO (1) WO2016043997A1 (es)
ZA (1) ZA201700826B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201742625A (zh) * 2016-03-15 2017-12-16 阿斯特捷利康公司 組合療法
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN109641052A (zh) * 2016-08-18 2019-04-16 伊莱利利公司 BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
KR20190077349A (ko) 2016-10-28 2019-07-03 하. 룬드벡 아크티에셀스카브 이미다조피라지논의 투여를 포함하는 병용 치료
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
RS62551B1 (sr) 2017-12-14 2021-12-31 H Lundbeck As Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3728250A1 (en) 2017-12-20 2020-10-28 H. Lundbeck A/S PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
US12350278B2 (en) 2018-06-27 2025-07-08 Joshua O. Atiba Therapy and prevention of prion protein complex infections in non-human animals
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
US20230236199A1 (en) * 2020-04-23 2023-07-27 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE424383T1 (de) 2003-08-08 2009-03-15 Schering Corp Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren
BRPI0906962B8 (pt) * 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
LT3339323T (lt) * 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
AP2017009794A0 (en) 2017-03-31
US9999624B2 (en) 2018-06-19
TWI599358B (zh) 2017-09-21
IL250387A0 (en) 2017-03-30
PH12017500493A1 (en) 2017-08-07
CN106687136A (zh) 2017-05-17
AR101740A1 (es) 2017-01-11
CA2956835A1 (en) 2016-03-24
EP3193882A1 (en) 2017-07-26
EA201790305A1 (ru) 2017-07-31
KR101871128B1 (ko) 2018-06-25
SV2017005389A (es) 2018-01-17
TW201618786A (zh) 2016-06-01
EA031764B1 (ru) 2019-02-28
ECSP17015977A (es) 2018-03-31
JP2017529348A (ja) 2017-10-05
CL2017000558A1 (es) 2017-11-10
TN2017000072A1 (en) 2018-07-04
DOP2017000071A (es) 2017-06-15
AU2015318257A1 (en) 2017-02-16
ZA201700826B (en) 2018-12-19
WO2016043997A1 (en) 2016-03-24
NZ728636A (en) 2018-05-25
CO2017001875A2 (es) 2017-05-19
PE20170464A1 (es) 2017-04-26
AU2015318257B2 (en) 2018-06-14
MX2017003414A (es) 2017-06-19
US20170224702A1 (en) 2017-08-10
BR112017003571A2 (pt) 2017-12-19
SG11201701330PA (en) 2017-04-27
JP6339741B2 (ja) 2018-06-06
KR20170036103A (ko) 2017-03-31

Similar Documents

Publication Publication Date Title
CR20170080A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
IL239981B1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2019001575A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
NZ712207A (en) Tetrahydropyrrolothiazine compounds
EA201691541A1 (ru) Новые анти-baff антитела
DOP2017000178A (es) Inhibidores selectivos de bace1
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
WO2016069477A3 (en) A method of treating cancer that overexpresses topbp1
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
EA201792282A1 (ru) Способы лечения заболеваний
MX2024008671A (es) Metodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina.
MX2016008968A (es) Compuestos organicos.
BR112018002763A2 (pt) método para cicatrização de ferimentos
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.